Imatinib mesylate is a drug that has been recently approved for the treatment for chronic myeloid leukemia. It acts as a potent and selective inhibitor of BCR-ABL tyrosine kinase. It also inhibits both c-kit and platelet-derived growth factor receptor tyrosine kinases. Hypopigmentation of the skin in patients receiving this drug has been recently reported. We report a 17-year-old Caucasian patient affected by chronic myeloid leukemia in therapy with imatinib mesylate who developed hypopigmented vitiligo-like patches and generalized lightening of the skin. In order to evaluate the lightening observed clinically, we measured the progressive skin color hypopigmentation by using a colorimeter over several months. The colorimetric evaluation confirmed the generalized and gradual lightening of patient's skin over treatment with imatinib mesylate. We believe that this is the first reported instance of vitiligo-like lesions in a pediatric patient treated with imatinib mesylate, and the second in a Caucasian patient. © 2006 The Authors.

Vitiligo-like lesions and diffuse lightening of the skin in a pediatric patient treated with imatinib mesylate: A noninvasive colorimetric assessment / Brazzelli, V.; Roveda, E.; Prestinari, F.; Barbagallo, T.; Bellani, E.; Trevisan, V.; Rona, C.; Locatelli, F.; Zecca, M.; Borroni, G.. - In: PEDIATRIC DERMATOLOGY. - ISSN 0736-8046. - 23:2(2006), pp. 175-178. [10.1111/j.1525-1470.2006.00208.x]

Vitiligo-like lesions and diffuse lightening of the skin in a pediatric patient treated with imatinib mesylate: A noninvasive colorimetric assessment

Locatelli F.;
2006

Abstract

Imatinib mesylate is a drug that has been recently approved for the treatment for chronic myeloid leukemia. It acts as a potent and selective inhibitor of BCR-ABL tyrosine kinase. It also inhibits both c-kit and platelet-derived growth factor receptor tyrosine kinases. Hypopigmentation of the skin in patients receiving this drug has been recently reported. We report a 17-year-old Caucasian patient affected by chronic myeloid leukemia in therapy with imatinib mesylate who developed hypopigmented vitiligo-like patches and generalized lightening of the skin. In order to evaluate the lightening observed clinically, we measured the progressive skin color hypopigmentation by using a colorimeter over several months. The colorimetric evaluation confirmed the generalized and gradual lightening of patient's skin over treatment with imatinib mesylate. We believe that this is the first reported instance of vitiligo-like lesions in a pediatric patient treated with imatinib mesylate, and the second in a Caucasian patient. © 2006 The Authors.
2006
...
01 Pubblicazione su rivista::01a Articolo in rivista
Vitiligo-like lesions and diffuse lightening of the skin in a pediatric patient treated with imatinib mesylate: A noninvasive colorimetric assessment / Brazzelli, V.; Roveda, E.; Prestinari, F.; Barbagallo, T.; Bellani, E.; Trevisan, V.; Rona, C.; Locatelli, F.; Zecca, M.; Borroni, G.. - In: PEDIATRIC DERMATOLOGY. - ISSN 0736-8046. - 23:2(2006), pp. 175-178. [10.1111/j.1525-1470.2006.00208.x]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1489371
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 25
  • ???jsp.display-item.citation.isi??? ND
social impact